Chugai’s Anti-IL-31 Receptor, gehumaniseerd monoklonaal antilichaam “nemolizimab”, langetermijngegevens van de wereldwijde fase ll studie gepubliceerd in Journal of Allergy en Clinical Immunology Online
TOKYO–(BUSINESS WIRE)–
— Gegarandeerde veiligheid en efficiëntie van nemolizumab voor eenjarige behandeling —
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) heeft vandaag aangekondigd dat de langetermijngegevens van een wereldwijde fase ll-studie (de XCIMA-studie) voor nemolizumab (CIM331) op 9 mei 2018 gepubliceerd is in het Journal of Allergy en Clinical Immunology Online.
“Nemolizumab bij matig tot ernstige atopische dermatitis: Gerandomiseerde fase ll langetermijn extensie studie” Kenji Kabashima, M.D., PH.D., et al.
https://www.jacionline.org/article/S0091-6749(18)30698-5/abstract
“Controle van chronische pruritus en ontsteking van de huid is cruciaal voor patienten met atopische dermatitis (AD). Deze gegevens van de uitbreiding op lange termijn die de doeltreffendheid en veiligheid van nemolizumab aantoonden versterkten het beeld dat nemolizumab een nieuwe behandelingsoptie voor de ziekte kan bieden”, stelt Dr. Yashushi Ito, Executive Vice President en mede-verantwoordelijk van Project & Lifecycle Management Unit. “De missie van Chugai is om bij te dragen aan de gesteldheid van patiënten met innovatieve geneesmiddelen. We zullen nauw samenwerken met onze partners – Galderma en Maruho – om AD-patiënten te helpen door deze nieuwe behandelingsmogelijkheden zo snel mogelijk te ontwikkelen.”
Chugai’s Anti-IL-31 Receptor A Humanized Monoclonal Antibody “nemolizumab,” Long Term Data from Global Phase II Study Published in Journal of Allergy and Clinical Immunology Online
TOKYO–(BUSINESS WIRE)–
— Confirmed Safety and Efficacy of nemolizumab for One Year Treatment —
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that the long-term data from a global phase II study (the XCIMA study) for nemolizumab (CIM331) was published in Journal of Allergy and Clinical Immunology Online on May 9, 2018.
“Nemolizumab in moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study” Kenji Kabashima, M.D., Ph.D., et al
https://www.jacionline.org/article/S0091-6749(18)30698-5/abstract
“Control of chronic pruritus and inflammation of the skin is crucial for patients with atopic dermatitis (AD). This long-term extension data which demonstrated efficacy and safety of nemolizumab reinforced anticipation that nemolizumab may offer a novel treatment option for the disease,” said Dr. Yasushi Ito, Executive Vice President, Co-Head of Project & Lifecycle Management Unit. “Chugai’s mission is to contribute to patients through innovative medicines. We will closely work together with our partners – Galderma and Maruho, towards helping AD patients by developing this new treatment option as quickly as possible.”
“I am delighted to see a steady development of the novel treatment which addresses pathogenesis of pruritus in atopic dermatitis,” said, Professor Kenji Kabashima, Kyoto University, the first author of the article. “I would like to carefully examine safety and efficacy of nemolizumab further, in the expectation of future clinical use.”
The study was conducted to evaluate safety and efficacy of nemolizumab in 264 patients with moderate-to-severe AD. The safety and efficacy of nemolizumab at 12 weeks, the study’s primary endpoint, were confirmed and published in The New England Journal of Medicine Online in March 2017. The data published this time was obtained to assess safety and efficacy of long-term administration. It confirmed that nemolizumab maintained its safety and efficacy after one year of continuous treatment.
About the results of the global phase II study
Press release issued in March 2, 2017.
https://www.chugai-pharm.co.jp/english/news/detail/20170302150000.html
Chugai granted the exclusive development and marketing rights of nemolizumab worldwide, excluding Japan and Taiwan, to Galderma and licensed out the development and marketing rights in the skin disease area to Maruho for the Japanese market respectively. Currently, Galderma is conducting a phase 2b study and Maruho is conducting a phase 3 study.
Please refer to the press release for the details of the license agreement with
Galderma: https://www.chugai-pharm.co.jp/english/news/detail/20160721083000.html
Maruho: https://www.chugai-pharm.co.jp/english/news/detail/20160928150000.html
About nemolizumab (CIM331)
Nemolizumab (CIM331) is a humanized anti-human IL-31 receptor A (IL-31RA) monoclonal antibody intending to be a first-in-class treatment. IL-31 is identified as a pro-inflammatory cytokine that can induce pruritus, inflammation, and skin barrier dysfunction in atopic dermatitis, as well as pruritus in dialysis patients1, 2, 3, 4). Nemolizumab is thought to work by inhibiting biological activity of IL-31 through competitively blocking the binding of IL-31 to its receptor.
Trademarks used or mentioned in this release are protected by law.
[References]
1. Sonkoly E, et al., IL-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117: 411-7.
2. Cornelissen C, et al., IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clinical Immunol 2012; 129: 426-33.
3. Kasraie S, et al., Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy 2010; 65: 712-21.
4. Ko MJ, et al., Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. J Am Acad Dermatol 2014; 71: 1151-9.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180509006663/en/
Contacts
For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Tomoko Shimizu
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp